Skip to main
BAX
BAX logo

Baxter (BAX) Stock Forecast & Price Target

Baxter (BAX) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 22%
Hold 56%
Sell 11%
Strong Sell 0%

Bulls say

Baxter International has demonstrated a solid financial trajectory, particularly in its Healthcare Systems & Technologies segment, which experienced sales growth of approximately 6% in the first quarter of 2025 and 2% in the second quarter, with projected growth rates of 4% and 2% for the third and fourth quarters, respectively. Additionally, the company has implemented pricing initiatives that are expected to contribute approximately 100 basis points to sales growth in 2024 and 2025, enhancing revenue stability. The strategic acquisition of Hillrom has further diversified Baxter's portfolio, positioning it favorably in the healthcare market and supporting its overall growth prospects.

Bears say

Baxter International has experienced a significant downturn in its financial performance, as evidenced by disappointing results in the second quarter of 2025, where sales, margins, and earnings per share all fell below consensus expectations. The company has struggled through a challenging operational period from 2021 to 2023, marked by a combination of external factors and internal missteps that resulted in mixed quarterly performances and multiple negative guidance revisions. Moreover, sales softness, manufacturing inefficiencies, and an unfavorable product mix have led to gross margins of 40.7%, which fell short of both the company’s and consensus estimates, along with operating margins of 15.1% that also missed consensus expectations by over 100 basis points.

Baxter (BAX) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 22% recommend Buy, 56% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Baxter (BAX) Forecast

Analysts have given Baxter (BAX) a Hold based on their latest research and market trends.

According to 9 analysts, Baxter (BAX) has a Hold consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Baxter (BAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.